Genexine, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1999-06-08
- Employees
- 101
- Market Cap
- -
- Website
- http://www.genexine.com
Phase I Study GX-G3 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: GX-G3 25 μg/kg or PlaceboDrug: GX-G3 100 μg/kg or PlaceboDrug: GX-G3 50 μg/kg or PlaceboDrug: GX-G3 12.5 μg/kg or Placebo
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2015-01-29
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT01951027
- Locations
- 🇰🇷
Chungnam National University Hospital, Jung-gu, Daejeon, Korea, Republic of
Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2013-12-30
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01813487
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients
Phase 1
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Genetic: HB-110
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01641536
- Locations
- 🇰🇷
Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3
Phase 1
Completed
- Conditions
- Cervical Intraepithelial Neoplasia 3
- Interventions
- Genetic: GX-188E administered by electroporation
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01634503
- Locations
- 🇰🇷
Cheil General Hospital & Women's Healthcare Center, Seoul, Korea, Republic of
Gene Therapy With GX-12 in Combination With HAART for the HIV-1 Infected Patients
Phase 1
- Conditions
- HIV Infections
- Interventions
- Genetic: GX-12Drug: HAART
- First Posted Date
- 2007-08-17
- Last Posted Date
- 2008-05-12
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00517569
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine
Phase 1
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Genetic: a mixed plasmid DNA (HB-110)
- First Posted Date
- 2007-08-09
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT00513968
- Locations
- 🇰🇷
Kangnam St. Mary's Hospital, Seoul, Korea, Republic of